Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124729 | 1.00 | MTNR1A (0.64) | MTNR1AMTNR1BHDAC8HTR2CHTR2B | |
| SCHEMBL7009577 | 0.87 | MTNR1A (0.66) | MTNR1AMTNR1BHDAC8MEN1ALDH1A1 | |
| SCHEMBL7009575 | 0.87 | MTNR1A (0.66) | MTNR1AMTNR1BHDAC8MEN1ALDH1A1 | |
| SCHEMBL7007025 | 0.84 | MTNR1A (0.62) | MTNR1AMTNR1BHDAC8HTR2CHTR2B | |
| SCHEMBL7007021 | 0.84 | MTNR1A (0.62) | MTNR1AMTNR1BHDAC8HTR2CHTR2B | |
| SCHEMBL7228520 | 0.82 | MTNR1A (0.59) | MTNR1AMTNR1BHDAC8CYP1A2 | |
| SCHEMBL7228521 | 0.82 | MTNR1A (0.59) | MTNR1AMTNR1BHDAC8CYP1A2 | |
| SCHEMBL10298599 | 0.79 | MTNR1A (0.62) | MTNR1AMTNR1BHTR2CHTR2BCYP1A2 | |
| SCHEMBL17183736 | 0.79 | ALDH1A1 (0.53) | MTNR1AMTNR1BHDAC8CYP1A2MEN1 | |
| SCHEMBL17183696 | 0.78 | ALDH1A1 (0.51) | MTNR1AMTNR1BHDAC8CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245363-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2012-09-27 | — | — | US | disclosed |
| US-8212077-B2 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2012-07-03 | — | — | US | disclosed |
| EP-2151428-B1 | Process for the preparation of agomelatin | SERVIER LAB (FR) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010015745-A1 | NOVEL METHOD FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | WO | disclosed |
| US-20100036162-A1 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2151428-A1 | Process for the preparation of agomelatin | Les Laboratoires Servier (FR) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245363-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | COMT, PNMT, TPH1 | MTNR1A 331/4885MTNR1B 293/4885HDAC8 4114/4885 |
| US-20100036162-A1 | Process for the synthesis of agomelatine | COMT, PNMT, TPH1 | MTNR1A 331/4885MTNR1B 293/4885HDAC8 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.